Lifecycle
Announced
stage pending
Spin-off detail
Aspire Biopharma Holdings, Inc. -> SpinCo
ASBPW / n/a ยท detected 2026-02-24
Triage
Monitor
MONITOR
Confidence
29%
detection/extraction
Listing
n/a
distribution n/a
Extracted thesis
Eastern Time, including at any adjournments or postponements of the special meeting, at 4626 N 300 W, Suite 350, Provo, UT 84604, for the purposes stated in the accompanying Notice of Special Meeting of Stockholders.
Proposal 3 (ELOC Issuance Proposal) to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 19.99% or more of our issued and outstanding common stock pursuant to the that certain Purchase Agreement (the “
We will include abstentions and broker non-votes in the calculation of the number of shares considered to be present at the meeting for purposes of determining the presence of a quorum at the meeting.
For purposes of the ELOC Issuance Proposal, abstentions and broker non-votes will not be counted as votes cast and will have no effect on the result of the vote, although they will be considered present for the purpose of determining the presence of a quorum.
If we issue additional shares of Common Stock for any of these purposes, the aggregate ownership interest of our current stockholders, and the interest of each such existing stockholder, would be diluted, possibly substantially.
Risk flags
Estimated float is unavailable from current filing data.
risk
Source Links
3-Year Financials
Revenue by year
Operating income or ebit by year
Margin by year
Margin trend
Ownership and float
Total shares0
Parent retained shares percent
Insider or management shares percent
Restricted or locked up shares
Estimated float percent
Assumption noteFloat estimate unavailable from filing text.
Management incentives
Management ownership percent
Equity comp alignment indicators["DATE OF NAME CHANGE: 20210222 DEF 14A 1 formdef14a.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(c) of the Securities Exchange Act of 1934 Filed by Registrant ☒", ") (3) to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 19.99% or more of our issued and outstanding common stock pursuant to that certain Purchase Agreement (the “", "Proposal 3 (ELOC Issuance Proposal) to approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 19.99% or more of our issued and outstanding common stock pursuant to the that certain Purchase Agreement (the “"]
Parent to spinoff leadership migration